Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Ann Surg Oncol ; 30(9): 5472-5485, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37340200

ABSTRACT

BACKGROUND: Involved lateral lymph nodes (LLNs) have been associated with increased local recurrence (LR) and ipsi-lateral LR (LLR) rates. However, consensus regarding the indication and type of surgical treatment for suspicious LLNs is lacking. This study evaluated the surgical treatment of LLNs in an untrained setting at a national level. METHODS: Patients who underwent additional LLN surgery were selected from a national cross-sectional cohort study regarding patients undergoing rectal cancer surgery in 69 Dutch hospitals in 2016. LLN surgery consisted of either 'node-picking' (the removal of an individual LLN) or 'partial regional node dissection' (PRND; an incomplete resection of the LLN area). For all patients with primarily enlarged (≥7 mm) LLNs, those undergoing rectal surgery with an additional LLN procedure were compared to those  undergoing only rectal resection. RESULTS: Out of 3057 patients, 64 underwent additional LLN surgery, with 4-year LR and LLR rates of 26% and 15%, respectively. Forty-eight patients (75%) had enlarged LLNs, with corresponding recurrence rates of 26% and 19%, respectively. Node-picking (n = 40) resulted in a 20% 4-year LLR, and a 14% LLR after PRND (n = 8; p = 0.677). Multivariable analysis of 158 patients with enlarged LLNs undergoing additional LLN surgery (n = 48) or rectal resection alone (n = 110) showed no significant association of LLN surgery with 4-year LR or LLR, but suggested higher recurrence risks after LLN surgery (LR: hazard ratio [HR] 1.5, 95% confidence interval [CI] 0.7-3.2, p = 0.264; LLR: HR 1.9, 95% CI 0.2-2.5, p = 0.874). CONCLUSION: Evaluation of Dutch practice in 2016 revealed that approximately one-third of patients with primarily enlarged LLNs underwent surgical treatment, mostly consisting of node-picking. Recurrence rates were not significantly affected by LLN surgery, but did suggest worse outcomes. Outcomes of LLN surgery after adequate training requires further research.


Subject(s)
Lymph Node Excision , Rectal Neoplasms , Humans , Lymph Node Excision/methods , Cross-Sectional Studies , Lymph Nodes/surgery , Lymph Nodes/pathology , Rectal Neoplasms/pathology , Rectum/pathology , Retrospective Studies , Neoplasm Recurrence, Local/surgery , Neoplasm Recurrence, Local/pathology , Neoplasm Staging
3.
Case Rep Gastrointest Med ; 2018: 5640379, 2018.
Article in English | MEDLINE | ID: mdl-29850293

ABSTRACT

Heterotopic pancreas is a relatively uncommon congenital anomaly, defined as pancreatic tissue in ectopic sites without an anatomic and vascular continuity with the main body of the pancreas. We report the case of a 58-year-old woman who was admitted to the hospital with the clinical suspicion of a mild, acute pancreatitis. Computed tomography, magnetic resonance imaging, transabdominal ultrasound, and endoscopic ultrasound revealed a normal orthotopic pancreas and the suspicion of a large heterotopic pancreas in the small bowel mesentery with signs of acute inflammation. The diagnosis of mesenteric heterotopic pancreatitis was preoperatively confirmed by endoscopic ultrasound-guided fine-needle aspiration and consequently histologically established after surgical resection.

4.
Circulation ; 119(6): 828-34, 2009 Feb 17.
Article in English | MEDLINE | ID: mdl-19188507

ABSTRACT

BACKGROUND: There are limited data on the long-term clinical outcome after an angiographically confirmed (definite) stent thrombosis (ST). METHODS AND RESULTS: Four hundred thirty-one consecutive patients with a definite ST were enrolled in this multicenter registry. The primary end point was the composite of cardiac death and definite recurrent ST. Secondary end points were all-cause death, cardiac death, definite recurrent ST, definite and probable recurrent ST, any myocardial infarction, and any target-vessel revascularization. The primary end point occurred in 111 patients after a median follow-up of 27.1 months. The estimated cumulative event rates at 30 days and 1, 2, and 3 years were 18.0%, 23.6%, 25.2%, and 27.9%, respectively. The cumulative incidence rates of definite recurrent ST, definite or probable recurrent ST, any myocardial infarction, and any target-vessel revascularization were 18.8%, 20.1%, 21.3%, and 32.0%, respectively, at the longest available follow-up. Independent predictors for the primary end point were diabetes mellitus, total stent length, severe calcification, American College of Cardiology/American Heart Association B2-C lesions, TIMI (Thrombolysis In Myocardial Infarction) flow grade <3 after percutaneous coronary intervention, and left ventricular ejection fraction <45%. The implantation of an additional coronary stent during the first ST was also associated with unfavorable outcome. Clinical outcome was not affected by the type of previously implanted stent (drug-eluting or bare-metal stent) or the category of ST (early versus late). CONCLUSIONS: The long-term clinical outcome after a first definite ST is unfavorable, with a high mortality and recurrence rate. Diabetes mellitus, left ventricular ejection fraction <45%, long total stent length, complex coronary lesions, TIMI flow grade <3 after percutaneous coronary intervention, and implantation of an additional coronary stent during the emergent percutaneous coronary intervention for the ST were associated with this unfavorable outcome.


Subject(s)
Coronary Thrombosis/epidemiology , Coronary Thrombosis/etiology , Stents/adverse effects , Aged , Angiography , Coronary Thrombosis/diagnosis , Coronary Thrombosis/mortality , Death , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Infarction , Recurrence , Registries , Risk Factors , Treatment Outcome
5.
Eur Urol ; 54(1): 221-5; quiz 225, 2008 Jul.
Article in English | MEDLINE | ID: mdl-17964710

ABSTRACT

The current practice of withdrawing antiplatelet therapy before major surgery has been challenged by the introduction of coronary drug-eluting stents (DESs) since evidence is accumulating that a DES requires dual antiplatelet therapy for at least a year. The authors present a case demonstrating difficulty in decision-making when it comes to appropriate perioperative antiplatelet therapy. The patient experienced a coronary stent thrombosis possibly due to discontinuation of clopidogrel prior to urologic surgery.


Subject(s)
Coronary Stenosis/therapy , Drug-Eluting Stents/adverse effects , Lymph Node Excision , Platelet Aggregation Inhibitors/administration & dosage , Prostatic Neoplasms/pathology , Thrombosis/etiology , Ticlopidine/analogs & derivatives , Aged , Clopidogrel , Coronary Stenosis/complications , Fatal Outcome , Humans , Immunosuppressive Agents/administration & dosage , Male , Paclitaxel/administration & dosage , Prostatic Neoplasms/complications , Ticlopidine/administration & dosage , Withholding Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...